Union Bancaire Privee UBP SA Boosts Stake in Bristol Myers Squibb Company $BMY

Key Points

• Union Bancaire Privee UBP SA boosted its stake in Bristol Myers Squibb by 3,477.6% in Q4, adding 491,876 shares to hold 506,020 shares valued at about $25.69 million.
• Bristol Myers Squibb reported $1.26 EPS for the latest quarter (missing the $1.65 consensus) with $12.50 billion in revenue, set FY2026 guidance of 6.05–6.35 EPS, and carries a consensus analyst target of $61.41 with an overall "Hold" rating.
• The company declared a quarterly dividend of $0.63 per share (annualized $2.52), a 4.3% yield, with an ex-dividend date of April 2 and payment on May 1.

Union Bancaire Privee UBP SA lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3,477.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 506,020 shares of the biopharmaceutical company's stock after acquiring an additional 491,876 shares during the period. Union Bancaire Privee UBP SA's holdings in Bristol Myers Squibb were worth $25,690,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. CVA Family Office LLC raised its position in Bristol Myers Squibb by 2.6% during the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company's stock valued at $404,000 after purchasing an additional 223 shares in the last quarter. MSH Capital Advisors LLC increased its position in shares of Bristol Myers Squibb by 2.9% during the 3rd quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company's stock valued at $362,000 after purchasing an additional 223 shares during the last quarter. Bell & Brown Wealth Advisors LLC increased its position in shares of Bristol Myers Squibb by 0.5% during the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company's stock valued at $1,925,000 after purchasing an additional 224 shares during the last quarter. Addison Advisors LLC lifted its position in Bristol Myers Squibb by 6.2% in the 3rd quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 232 shares during the last quarter. Finally, Mccarter Private Wealth Services LLC lifted its position in Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company's stock worth $222,000 after buying an additional 235 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

BMY has been the topic of a number of recent research reports. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "neutral" rating in a research report on Friday, February 6th. HSBC upped their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research note on Tuesday. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Morgan Stanley reissued an "underweight" rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $61.41.

Bristol Myers Squibb Stock Down 2.0%

Shares of Bristol Myers Squibb stock opened at $58.17 on Friday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company's 50 day moving average price is $58.57 and its 200-day moving average price is $51.74. The stock has a market capitalization of $118.46 billion, a price-to-earnings ratio of 16.86, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.